Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465130 | 0.76 | CYP1A2 (0.45) | SMN1; SMN2CYP1A2GAACA12CA1 | |
| SCHEMBL4464960 | 0.73 | SMN1; SMN2 (0.37) | SMN1; SMN2CYP1A2GAACA12CA1 | |
| SCHEMBL761108 | 0.72 | PTPN2 (0.43) | — | |
| SCHEMBL755766 | 0.68 | JAK2 (0.43) | CYP1A2GAA | |
| SCHEMBL3409415 | 0.65 | CYP1A2 (0.73) | SMN1; SMN2CYP1A2GAAOPRM1 | |
| SCHEMBL193707 | 0.64 | CYP1A2 (0.71) | SMN1; SMN2CYP1A2GAA | |
| SCHEMBL16876699 | 0.64 | SMN1; SMN2 (0.63) | SMN1; SMN2CYP1A2CA12CA1CA2 | |
| SCHEMBL17140740 | 0.63 | SMN1; SMN2 (0.34) | SMN1; SMN2CYP1A2GAACA12CA1 | |
| SCHEMBL22440096 | 0.63 | GAA (0.42) | CYP1A2GAA | |
| SCHEMBL17140651 | 0.63 | SMN1; SMN2 (0.44) | SMN1; SMN2CYP1A2GAACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399473-B2 | Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2073635-B1 | MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20100029701-A1 | MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029701-A1 | MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, APP | SMN1; SMN2 1685/4885CYP1A2 774/4885GAA 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.